The global push to use artificial intelligence to find new medicines faces a crucial test as one front-runner starts approaching late-stage trials for a drug discovered by algorithms.

Insilico Medicine — which has headquarters in Hong Kong and New York — used AI to develop an experimental drug for the incurable lung disease idiopathic pulmonary fibrosis. The treatment is in mid-stage trials in the US and China with some results expected early 2025.